Clin2
NCT05087745Possibly a fitRecruiting

TIL therapy for advanced solid tumors

Advanced Solid TumorTumor Infiltrating LymphocytesTreatment Side EffectsEffects of Immunotherapy

Treatments studied

Part of Cancer, Immune system & allergy clinical trials.

This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
50 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have a solid tumor that has spread or come back, and standard treatments have not worked or are not available.
  • You have a tumor that can be biopsied or removed to collect immune cells, and you have at least one other tumor that can be measured.
  • Your overall health is reasonably good, with a life expectancy of more than 3 months.
  • Your blood counts and organ function are within required limits.
  • You must be willing to use effective birth control for a year after treatment if you could become pregnant or get someone pregnant.
  • You have not had anti-cancer treatment in the 28 days before the cells are collected.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05098197Recruiting· Early Phase 1
Study of TIL cell therapy for advanced liver, bile, or pancreas cancer

This trial studies a treatment called TIL therapy, which uses your own immune cells grown from a tumor sample, to treat advanced cancers of the liver/bile ducts or pancreas. It’s mainly for people whose standard treatments have already failed (or none exist), and who can safely provide tumor tissue for the cell preparation.

Shanghai, Shanghai Municipality
NCT06488950Recruiting· Early Phase 1
TIL therapy for advanced solid tumors

This trial tests a new type of personalized cell therapy (TIL) for people with advanced solid tumors who have run out of standard treatment options. It aims to see if this approach can help shrink tumors.

Shanghai
NCT05098184Recruiting· Early Phase 1
Study TIL treatment for advanced melanoma using harvested tumor cells

This early-phase trial tests GC101 TIL, a treatment made from your own melanoma tumor cells, for advanced melanoma. It may help the immune system better fight the cancer after standard treatments have already stopped working or if none are available.

Shanghai
NCT05142475Recruiting· Early Phase 1
Study of GC101 tumor-infiltrating cells for advanced breast cancer

This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.

Shanghai
NCT04967833Recruiting· Early Phase 1
Testing TIL cell therapy for advanced solid tumors

This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.

Shanghai
NCT06144671Recruiting· Phase 1/Phase 2
Custom immune cell therapy for advanced solid tumors

This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.

Shanghai, Shanghai Municipality

Hear when a new Advanced Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.